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Recent advances in cancer immunotherapy have directly built on 50 years of fundamental and technological
advances that made checkpoint blockade and T cell engineering possible. In this review, we intend to show
that research, not specifically designed to bring relief or cure to any particular disease, can, when creatively
exploited, lead to spectacular results in the management of cancer. The discovery of thymus immune func-
tion, T cells, and immune surveillance bore the seeds for today’s targeted immune interventions and chimeric
antigen receptors.Nanos gigantum humeris insidentes. (Like dwarfs sitting
on the shoulders of giants.)
—Bernard de Chartres (1120)
If I have seen further than others, it is by standing on the
shoulders of giants.
—Isaac Newton (1676)
The immune system is the guardian of our organismal integrity
in protecting us from infectious and other foreign invaders, such
as grafts and certain tumors. Immunology and oncology thus
have a long relationship, in evolutionary terms as well as within
the biomedical sciences. The two fields have intersected again
and again over the past half-century. We recount here some of
these events, with a deliberate focus on T lymphocytes—from
their discovery to their genetic engineering and use in cancer
immunotherapy. Insightful observations into leukemogenesis
in mice were at the root of the discovery of thymopoiesis
and lymphocyte subsets. Subsequent observations led to the
concept of immune surveillance, with eventual controversies
on the role of immunity in tumor prevention and protection that
were reconciled in the cancer immunoediting hypothesis. As
progress wasmade in our fundamental understanding of antigen
recognition, T cell activation, and T cell costimulation, transla-
tional researchers began to exploit the accumulating knowledge
for cancer therapy. Tumor-infiltrating T cells were harnessed for
adoptive cell therapy in a subset of melanoma patients; cancer
vaccines were developed in an attempt to amplify endogenous
tumor-specific T cell responses. Two of the most recent, most
exciting therapeutic developments rest on the manipulation of
costimulatory pathways governing T cell function. One, based
on monoclonal antibody technology, enables the release of tu-
mor-infiltrating T cells from inhibition mediated by costimulatory
receptors such as CTLA-4 and PD-1, through either checkpoint
blockade or depletion of regulatory T cells. The other, based on
gene transfer technology, enables to repurpose patient’s T cells,
targeting them to tumor antigens and augmenting their func-
tional properties to overcome barriers erected by tumor cells
and their microenvironment. These two forms of cancer immu-notherapy were recognized by the Science magazine as the
‘‘breakthrough of the year’’ in 2013 (Couzin-Frankel, 2013) and
by the US Food and Drug Administration, which approved the
anti-CTLA-4 monoclonal antibody Ipilimumab in 2011 and
granted breakthrough status to the CD19-specific chimeric anti-
gen receptors (CARs) utilized at the University of Pennsylvania
and Memorial Sloan Kettering Cancer Center for the treatment
of pediatric and adult acute lymphoblastic leukemia in 2014.
In this review, we aim to expose how basic discoveries in immu-
nology led to these promising advances in cancer therapy.
Leukemogenesis, the Thymus and Immunological
Ontogeny
Prior to 1960, the thymus was thought to be a vestigial organ that
had become redundant during evolution and was just a grave-
yard for dying lymphocytes. Even though recirculating small
lymphocytes had been found by Gowans (Gowans et al., 1962)
to be immunocompetent cells able to initiate either cellular or hu-
moral immune responses, thymus lymphocytes were deemed
immunoincompetent since they did not recirculate, nor could
they transfer immune responses to appropriate recipients.
Furthermore, thymectomy, which had always been performed
in adult animals, had no untoward effects on immune capacity.
In 1959–1961, however, results obtained in a mouse model of
lymphocytic leukemia induced by the Gross leukemia virus led
to experiments using neonatally thymectomized mice.
To obtain a high incidence of leukemia in mouse strains that
were not highly prone to develop this malignancy, the virus had
to be given at birth, and not later (Gross, 1951). Thymectomy
of virus-inoculatedmice at 1month of age prevented the disease
(Miller, 1959a), and grafting a neonatal thymus as late as
6 months after adult thymectomy restored the potential for
leukemia development (Miller, 1959b). Clearly, the virus must
have remained latent, and indeed, it could be recovered from
the non-leukemic tissues of thymectomized mice not grafted
with thymus tissue (Miller, 1960).
It was surmised that to induce a high percentage of leukemia in
low-leukemic strains ofmice, the virus had to be given neonatally
because it needed to multiply in some cells present only in a
newborn thymus. To test this hypothesis, the virus was givenCancer Cell 27, April 13, 2015 ª2015 Elsevier Inc. 439
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the prediction that thymus grafting performed later would not
restore leukemogenesis. The neonatally thymectomized mice
fared well until some weeks after weaning, when many became
sick, wasted, and died. This had never been seen by anyone who
had thymectomized adult mice (Miller, 1961a). Post-mortem
examination revealed lesions in the liver suggestive of mouse
hepatitis virus infection and marked diminution of lymphocytes
in the blood and in the lymphoid tissues (Miller, 1961b, 1962a).
As lymphocytes were known to be involved in graft rejection
and other immune responses, the neonatally thymectomized
mice were tested for immunocompetence by grafting them
with foreign skin before they had begun to show signs of wasting
disease. Remarkably, they failed to reject foreign skin grafts,
even when donors and recipients differed at the major histo-
compatibility locus, H-2 (Miller, 1961b, 1962a). The neonatally
thymectomized mice also lacked the ability to produce a normal
antibody response to certain antigens, such as Salmonella typhi
H antigen (Miller, 1962a) and sheep erythrocytes (Miller et al.,
1965).
Thymus grafting restored immune potential, and grafting of a
foreign thymus induced specific tolerance to skin from the donor
of the thymus graft (Miller, 1962a). This suggested that the
thymus may be the seat where tolerance is learned: ‘‘Antigenic
material might make contact with certain cell types differenti-
ating in the thymus and in some way prevent these cells from
maturing to a stage when they would be capable of reacting
immunologically’’ (Miller, 1962a). This clear prediction of nega-
tive selection was proven some years later by using the so-called
super antigens and transgenic mice, and both positive and
negative selection of thymocytes were then worked out (Bevan,
1977; Kappler et al., 1987). The major events in thymus cell dif-
ferentiation have been summarized in a recent Timeline review
(Miller, 2011).
It seemed important to determine whether the thymus exerted
its influence by seeding cells into the rest of the lymphoid sys-
tem. Since no cell-surface markers had at that time been found
to identify cells from different locations, use was made of the
T6 strain of mice, the cells of which could be identified at meta-
phase by the presence of two minute chromosomes. Neonatally
thymectomized F1 hybrid mice, in which one parent was T6,
were grafted with thymus from the other parental strain and
immunized with skin from various donors. An analysis of the
chromosome constitution of the cells in metaphase in the
spleen showed that 15% to 20% had originated from the thymus
graft (Miller, 1962a). This suggested that the thymus did produce
cells capable of migrating to the periphery and that presumably
such recent thymus emigrants would have just matured before
leaving or would mature in the peripheral lymphocyte pool to
become fully competent lymphocytes.
Although adult thymectomy had no effect on immunological
capacity, it could conceivably have caused a problem in mice
whose lymphoid system had been destroyed in some way, as
for example by total-body irradiation. This proved to be the
case in partially irradiated mice (Miller, 1962c) and in lethally
irradiated mice protected with bone marrow (Cross et al.,
1964). The use of adult thymectomized, heavily irradiated mice
protected with bone marrow (ATxBM mice) proved invaluable
for further elucidation of immune functions.440 Cancer Cell 27, April 13, 2015 ª2015 Elsevier Inc.All of these results were initially regarded with some skepti-
cism. Vague criticisms abounded, such as the one stating that
mice must be unusual and that the results obtained would never
be seen in humans. What needed to be checked, however, was
that because the mice used had been raised in converted horse
stables, the added trauma of neonatal thymectomy made them
highly susceptible to infections. This criticismwas soon quashed
when it was shown that mice reared in a germfree facility, when
thymectomized at birth did not develop wasting disease and yet
were unable to reject skin grafts, even those that differed at the
H-2 locus (McIntire et al., 1964). In 1968, the nude mouse was
discovered (Rygaard, 1973), and immunologists no longer had
doubts about the immunological function of the thymus.
In children with thymus aplasia, as in di George syndrome,
thymus transplantation has reversed immunodeficiency (August
et al., 1970). The problem lies in donor availability and tissue
compatibility. However, the recent spectacular success in
creating a functional thymus organ by enforcing Foxn1 expres-
sion to reprogram mouse embryonic fibroblasts into fetal thymic
epithelium (Bredenkamp et al., 2014) constitutes a first prom-
ising step in the provision of appropriate thymus tissue.
The Identification of T and B Cells in Mice
As stated before, Gowans had clearly shown that recirculating
small lymphocytes could respond both by a cellular immune
response (as in skin graft rejection) and by producing antibody
(Gowans et al., 1962). He considered that the same cell could
take part in either, depending on the antigenic stimulus. As
neonatally thymectomized mice were deficient in both cellular
and at least some humoral responses, it was urgent to show
that they had markedly reduced numbers of recirculating lym-
phocytes, not just blood lymphocytes. This was performed after
cannulating the thoracic duct of neonatally thymectomized and
ATxBMmice and collecting the lymph over a 24- to 48-hr period
(Miller et al., 1967; Miller andMitchell, 1967). The conclusion was
made that most thoracic duct lymphocytes (TDLs) in mice were
thymus derived, and this was actually proven in subsequent
experiments (Miller and Sprent, 1971).
But were the same cells involved in antibody production and
skin graft rejection? Two experimental systems suggested that
this might not be the case. Claman (Claman et al., 1966) showed
that irradiated mice given syngeneic bone marrow cells and
syngeneic thymus cells could produce more antibody than
when given either cell source alone. As no antibody markers
were available at the time, the origin of the antibody-forming cells
could not be easily identified. The situation was different for
chickens in Burnet’s laboratory, where impairment of bursa func-
tion by testosterone injection caused the birds not to produce
antibody, whereas thymus atrophy in sick birds prevented graft
rejection (Warner et al., 1962). Because mammals do not have
a bursa, Burnet (Burnet, 1962) surmised, ‘‘In mammals it is highly
probable that the thymus also carries out the function of the
bursa of Fabricius in the chicken, which is to feed into the
body the cells whose descendants will produce antibody.’’
In 1967 and 1968,Miller andMitchell (Miller andMitchell, 1967,
1968, 1969), reconstituted neonatally thymectomized and adult
thymectomized, irradiated CBA strain mice with CBA bone
marrow and (CBAXC57BL)F1 TDLs and challenged them with
sheep erythrocytes. The ATxBM mice in those experiments
Figure 1. The Origins of T Cells and B Cells
Percent reduction of antibody-forming cells per spleen of adult thymectomized
and heavily irradiated CBA protected with CBA bone marrow (ATxXBM), given
(CBAXC57BL)F1 thoracic duct lymphocytes, and challenged with sheep
erythrocytes. To the incubation mixture was added normal mouse serum
(NMS; slightly toxic), C57BL anti-CBA serum (aCBA), or CBA anti-C57BL
serum (aC57BL) as shown. The number of mice providing spleens in each
group was three to six. Adapted from Mitchell and Miller (1968). These ex-
periments demonstrated the existence of thymus-derived cells (later known
as T cells) that were not antibody formers but were essential to allow cells
derived from the bone marrow (later known as B cells) to produce antibody
to certain antigens (later known as thymus-dependent antigens).
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ing cells were produced that lysed sheep erythrocytes. This was
shown by plaques when sheep red cells and spleen cells were
layered onto agar plates. Now the timewas appropriate to deter-
mine whether the TDLs gave rise to antibody-forming cells. It
was done by simply adding to the plates antiserum against
CBA strain antigens made by immunizing C57BL mice with
CBA tissues or antiserum against C57BL made in CBA mice.
The latter would be expected to kill any antibody-forming cells
if they were derived from the (CBAXC57BL)F1 TDL and hence
from the thymus-derived cells (Figure 1). The results were spec-
tacular, showing beyond any doubt that the antibody-forming
cells did not originate from the TDLs, but rather from the bone
marrow (Mitchell and Miller, 1968). It proved that lymphocytes
could be subdivided into two major groups: thymus-derived
cells (later known as T cells) were not antibody formers but
were essential to allow cells derived from the bone marrow (later
known as B cells) to produce antibody in response to certain
antigens (later known as thymus-dependent antigens). They
were thus helper cells collaborating with other cell types, derived
from the bone marrow, to enable these to produce antibody. The
murine equivalent of the bursa was thus the bone marrow.
The existence of two major lymphocyte subsets was first
regarded with some skepticism. At a meeting in Brooke Lodge
(Augusta, Michigan) held in 1968, Good was ‘‘concerned at
separating thymus-derived from marrow-derived cells’’ since
the former ‘‘are in fact marrow derived-cells.’’ He also claimed
to ‘‘have evidence that in the rabbit it (the bursa equivalent) re-
sides in the ilial lymphoid tissue and in the lymphoid tissue of
the appendix’’ (Good, 1969). At the same meeting, Gowans
(Gowans, 1969), who had proven that recirculating small lym-
phocytes were immunocompetent, stated, ‘‘Had it not been forDr Miller’s experiments I would have assumed that a single
variety of small lymphocyte was involved in each of our experi-
ments. If we have two cell lines that are collaborating, then
we have specificity residing in two cell lines, one thymus-derived
and the other marrow-derived. The problem is to bring these two
specific cell lines together. Does this necessity for the two cells
to find one another raise problems? It seems an inefficient mech-
anism if it rests only on chance contacts.’’ The then Professor of
Immunology at the National University in Canberra, Australia,
offered a less diplomatic critique and simply likened B and
T cells to the first and last letter of the word ‘‘bullshit.’’
The above somewhat simple experiments, performed without
the use of modern technologies such as gene targeting, cluster
of differentiation (CD) antigens, monoclonal antibody, and flow
cytometry, changed the course of immunology. Thus, the exis-
tence of T and B cells required a reinvestigation of numerous
immunological phenomena in terms of the role played by the
two distinct cell types, including the carrier effect, immunological
tolerance, immunological memory, immunodeficiency, autoim-
munity, and genetically determined immune responsiveness.
An avalanche of work soon followed as investigations were
focused on defining and investigating further lymphocyte sub-
sets and their function.
It was clear that the antigen recognition receptor on B lympho-
cytes was immunoglobulin (Ig), but controversy raged concern-
ing the nature of the T cell receptor (TCR) for antigen. Some
argued strongly in favor of the existence of a different type of
Ig molecule (IgT) (Marchalonis et al., 1972). Others, however,
showed that Ig on T cells had originated from B cells and bound
to the T cell Fc receptor (Hudson et al., 1974) and that no RNA
molecules bearing Ig VH nucleotide sequences could be de-
tected in T cells (Kemp et al., 1982). The discovery of monoclonal
antibodies (Ko¨hler and Milstein, 1975) was finally instrumental in
elucidating the TCR structure, and its coding sequences were
soon cloned independently in mouse and man (Hedrick et al.,
1984; Yoshikai et al., 1984). The TCR chains (a and b, or in
some cases g and d) are highly homologous to Ig and are
associated on the T cell membrane with CD3, a complex of three
polypeptides, g, d,and ε, and with a disulphide-linked z-z homo-
dimer or z-h heterodimer (Gold et al., 1986). These complexes
not only regulate the assembly and expression of the TCR, but
are also responsible for trans-membrane transduction of signals
after antigen occupation (Oettgen et al., 1985). The demonstra-
tion that the TCR was sufficient to direct antigen specificity in
transgenic mice (Dembic et al., 1986) would set the stage for
TCR-based T cell engineering two decades later.
Since T and B cells utilize different molecules as antigen-spe-
cific receptors, do they perceive antigen in different ways? This is
indeed the case: whereas B cells can bind soluble antigen,
T cells generally recognize antigen only if displayed on the sur-
faces of antigen-presenting cells (APCs), such as dendritic cells
(Steinman and Cohn, 1973) or virus-infected cells. Cytotoxic
T cells isolated from mice recovering from a virus infection
were tested for their capacity to kill virus-infected target cells
in vitro. Killing was observed but only if the target cells had the
same major histocompatibility complex (MHC) haplotype as
the mice from which the T cells were obtained (Zinkernagel
and Doherty, 1974). This suggested that there might be an asso-
ciation between a virus product and MHC molecules at the cellCancer Cell 27, April 13, 2015 ª2015 Elsevier Inc. 441
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MHC molecules and virus-encoded products. The phenomenon
became known as MHC restriction and the MHC molecules
involved as restriction elements. T cells in fact recognize
relatively short peptide fragments (Townsend et al., 1986) that
become wedged in the jaws of the MHC molecules. How
T and B cells perceive antigen is highly relevant for tumor
immunity and the escape of immunogenic tumor cells from any
host immune response. Loss of cell-surface antigen or MHC
molecules from genetically unstable tumor variants would of
course prejudice or prevent the response of any specific B and
T cells. CARs would later capitalize on the respective advan-
tages of both targeting modalities—and Ig VH genes would
make their way into T cells, after all (see below).
Further T cell subsets and their function were soon identified:
CD4 and CD8 T cells (Kisielow et al., 1975; Cantor and Boyse,
1975), natural killer T (NKT) cells (Makino et al., 1995; Godfrey
et al., 2004), and CD4+CD25+FoxP3+ regulatory T (Treg) cells
(Sakaguchi et al., 1985). Self-tolerance, as mentioned above,
is mostly achieved intra-thymically by negative selection of
self-reactive thymocytes. Since, however, some self-reactive
T cells (e.g., those with low affinity to self-antigens) escape to
the periphery, a peripheral tolerancemechanism exists, enabling
Treg cells to prevent autoimmunity (reviewed in Josefowicz et al.,
2012). Treg cells are either produced in the thymus during T cell
development (natural Treg [nTreg] cells) or induced from naive
CD4+ T cells in the periphery (so-called induced Treg [iTreg]
cells) and are marked by expression of the transcription factor
Foxp3 (Sakaguchi and Powrie, 2007). These cells soak up inter-
leukin-2 (IL-2) (Smith, 1989) through their high-affinity trimeric
IL-2 receptor, thus depriving other T cells of this growth factor,
but the exact mechanism by which, when recruited into the
tumor environment, they prevent the activity of other immune
cells capable of destroying the tumor is not clear. It may involve
the production of inhibitory cytokines such as transforming
growth factor (TGFb) (Powrie et al., 1996), IL-10 (Asseman
et al., 1999), and IL-35 (Collison et al., 2007).
It is not the aim of this review to describe in further detail each
of the key advances that have led to our current knowledge of
the function of T and B cells, since this has been extensively
covered recently in a Timeline review (Miller, 2011). It is note-
worthy that several genes that govern T cell development or
function, e.g., those encoding the IL receptor common g chain,
theWiskott-Aldrich syndrome protein, and others, are now being
developed as genetic therapies for the treatment of severe
immunodeficiencies (Fischer et al., 2013)
From Immune Surveillance to Cancer Vaccines
and Adoptive T Cell Therapy
The finding that neonatally thymectomized mice were more sus-
ceptible than normal mice to the cancer-producing activities of
strong carcinogens (e.g., 3,4-benzopyrene) (Miller et al., 1963)
and polyoma virus (Miller et al., 1964), (Miller, 1967) provided
some experimental support for Paul Ehrlich’s concept of immu-
nological surveillance (Ehrlich and Himmelweit, 1957): ‘‘I am
convinced that during development and growth malignant cells
arise extremely frequently, but in the majority of people they
remain latent due to the protective action of the host. I am also
convinced that this natural immunity is not due to the presence442 Cancer Cell 27, April 13, 2015 ª2015 Elsevier Inc.of antimicrobial bodies but is determined purely by cellular fac-
tors. These may be weakened in older age groups where cancer
is more prevalent.’’ Burnet echoed this view in his paper on tu-
mor immunosurveillance (Burnet, 1971).
A large amount of work has been done by many to determine
the importance of immunocompetent lymphocytes in guarding
against the emergence of neoplastic clones of cells. There is
no doubt that a deficiency of such cells is associated with an
increased incidence of those neoplasms that happen to be
strongly immunogenic and to be produced by strong carcino-
gens as cited above (Miller et al., 1963). However, extensive
studies performed using athymic nude mice failed to provide
any evidence of an increased susceptibility to the development
of spontaneous tumors (Rygaard and Povlsen, 1976). On the
other hand, RAG-deficient mice (lacking T, B, and NKT cells)
do spontaneously develop gastrointestinal epithelial malig-
nancies by the age of 18 months (Shankaran et al., 2001);
immunocompromised pathogen-free severe combined immu-
nodeficiency (SCID) mice have a high incidence of spontaneous
thymic lymphomas, and about 2%of retired breeders developed
a variety of non-thymic tumors (Huang et al., 2011).
It is well established that immunosuppressed humans, e.g.,
following therapy for transplantation, have an increased inci-
dence of tumors such as skin or cervical carcinomas and lym-
phomas (Penn and Starzl, 1973). A key question is whether this
is the result of failed immunosurveillance or of increased suscep-
tibility to infection by potentially oncogenic viruses (human papil-
lomavirus, hepatitis C virus, human immunodeficiency virus, and
Epstein-Barr virus [EBV]).
Many of the antigens expressed by spontaneous tumors are
expected to be self-antigens, and hence thymus-derived lym-
phocytes responding to these antigens would have been deleted
in the thymus. Low-affinity cells specific for these self-antigens
may, however, have escaped deletion and migrated to the pe-
riphery, where they may be held in check by the growing tumors
as described below. Some spontaneous tumors have a high fre-
quency of mutations that may therefore generate de novo anti-
gens (e.g., BCR-Abl, mutated forms of p53) that will not have
been present in the thymus and may thus appear foreign to the
immune system (Coulie et al., 2014; Gubin et al., 2014). In these
cases, therefore, both T cells and antibodies directed to tumor
antigens should be able to eliminate the tumor. It is, however,
not clear how likely it is that a point mutation in a single oncogene
would give rise to an antigenic peptide. In some instances,
pathogen-elicited thymus-derived cells that cross-react with
neoantigens acquired through somatic mutation may contribute
to anti-tumor responses (Snyder et al., 2014).
The bulk of the observations on immune surveillance have in
fact shown that T cells and antibodies could recognize and elim-
inate tumors (Boon et al., 1994). How tumors spontaneously
generate tumor immunity has led to the cancer immunoediting
hypothesis (Schreiber et al., 2011). This consists of three
sequential phases: elimination, equilibrium, and escape. In the
first phase, tumors developing before being clinically apparent
are destroyed and eliminated by both innate and adaptive im-
mune mechanisms (e.g., Shankaran et al., 2001). If variants arise
and fail to be eliminated, cells of the adaptive immune system
may restrain their growth during the lifetime of their host and
a state of equilibrium is reached. Constant immune selective
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variants that can no longer be recognized by effector T cells
because they have downregulated antigen or MHC, secreted
immunosuppressive cytokines such as TGFb or IL-10, or
recruited Treg cells in their environment. They then enter the
escape phase and become clinically apparent.
The administration of a cancer vaccine, such asGVAX (Dranoff
et al., 1993), has been used in themanagement of non- or weakly
immunogenic cancers. GVAX expresses tumor antigens in the
context of two important adjuvant activators, granulocyte-
macrophage colony-stimulating factor (GM-CSF) and pathogen
associated molecular patterns (PAMPs), that promote the acti-
vation of T cells with low affinity for self-antigens expressed by
tumors. This vaccine, together with the DNA-damage-inducing
chemotherapeutic drug cyclophosphamide that preferentially
targets Treg cells in a mixed cell population (Ghiringhelli et al.,
2007), with further assistance from the dual cocktail of anti-
CTLA-4 plus anti-PD-1 (or anti-PD-L1) antibodies, discussed
below, may be successful in the treatment of certain tumors—
if potent, truly tumor-specific T cell responses are indeed eli-
cited. This goal may be harder to reach in tumors with a low
rate of mutations (Alexandrov et al., 2013).
The focus on T cell responses inspired yet another approach in
cancer immunotherapy, pioneered by Rosenberg and col-
leagues, focusing directly on the patient’s own tumor-infiltrating
lymphocytes (TILs) when those exist and are accessible. In TIL
therapy, T cells retrieved from surgical melanoma specimens
are cultured under activating conditions and reinfused with IL-2
(Rosenberg et al., 1986) after host preconditioning (Gattinoni
et al., 2006). This approach is, however, not applicable to all
melanoma patients nor many other cancers. In EBV-associated
lymphoproliferative disease, for which EBV-transformed B cells
uniquely serve as effective APCs for tumor antigens of viral
origin, tumor-specific T cell lines have been successfully gener-
ated from peripheral blood of healthy donors and used to treat
immunocompromised recipients (Papadopoulos et al., 1994;
Heslop et al., 1996). Artificial APC systems substituting for
EBV-transformed B cells or dendritic cells (Kim et al., 2004)
have since been developed to facilitate the selection and/or
expansion of therapeutic T cells.
From T Cell Activation Biology to Checkpoint Blockade
and T Cell Engineering
Most spontaneous tumors express self-antigens and present
peptides derived from them embedded in MHC proteins on their
cell surface. T cells with high-affinity TCRs for these would have
been deleted by negative selection in the thymus. In melanomas,
which are known to undergo a high mutation rate (Berger et al.,
2012), some mutated peptides are displayed as altered self-
antigens on the cell surface, where they can be recognized by
cytotoxic CD8 T cells. So why are these immunogenic tumors
not spontaneously killed by activated CD8 cells? Extensive
studies of the molecules and processes involved in T cell acti-
vation have shed light on this conundrum and yielded levers to
enable or restore T cell function.
T cell activation initially requires two signals, one from the
recognition of antigen-derived peptides displayed in the context
of MHC molecules on the surface of APCs and one from the
interaction of the T cell costimulatory molecule CD28 with itsligands CD80 (B7-1) and CD86 (B7-2) on the APC (Lafferty and
Cunningham, 1975; Harding et al., 1992). Additional costimula-
tory receptors support T cell expansion and the maintenance
of T cell memory (Croft, 2003). Both activating and costimulatory
molecules would eventually be turned into powerful anti-cancer
agents, via very different therapeutic strategies, one based
on monoclonal antibody technology and the other on genetic
engineering.
Reversing Tumor-Protective Immune Inhibition
Under normal circumstances, T cell responses are regulated
by inhibitory checkpoints, mediated in part by CTLA-4 (CD152),
PD-1 (CD279), and BTLA (CD272), to prevent unrestrainedmulti-
plication, collateral damage by cytotoxic effector molecules, and
even autoimmunity.
CTLA-4 competes with CD28 for the ligands CD80 and CD86
and acts as a signal dampener during the early stages of activa-
tion of naive and memory T cells, in fact 24–48 hr after antigen
presentation (Krummel and Allison, 2011). It has been shown
to act as an effector molecule that inhibits CD28 costimulation
by the cell-extrinsic depletion of its ligands (Qureshi et al.,
2011). CTLA-4 is expressed on T cells, and its main physiological
function is to down-modulate CD4 T helper cell activity and
increase CD4+CD25+FoxP3+ Treg-cell-mediated immunosup-
pression (reviewed by Pardoll, 2012). A deficiency or mutation
in CTLA-4 in humans has contributed to the development of
autoimmune diseases including autoimmune hypothyroidism,
type I diabetes, systemic lupus erythematosus, and celiac dis-
ease (reviewed by Watanabe and Nakajima, 2012). Recently, a
heterozygous nonsense mutation in exon 1 of CTLA4 has been
identified in one of the commoner subgroups of common
variable immunodeficiency syndromes (CVIDs) characterized
by hypogammaglobulinemia, recurrent infections, and multiple
autoimmune manifestations (Schubert et al., 2014).
PD-1 is expressed following T cell activation and during
chronic antigen-induced T cell stimulation, and it limits the activ-
ity of T cells that have already been activated (Keir et al., 2008).
Unlike CTLA-4, PD-1 is expressed not only on all T cells subsets
but also on activated B cells and NK cells. It exerts its main func-
tion during the inflammatory response associated with infection.
Chronic antigen exposure, as occurs in certain viral infections,
can induce exhaustion of cognate antigen-specific activated
T cells. Furthermore, signals from inflammatory tissues induce
the expression of the PD-1 ligands, PD-L1 (B7-H1) or PD-L2
(B7-DC), that downregulate T cell activity, thereby limiting collat-
eral damage and even autoimmunity. As with CTLA-4, mutations
in PD-1 have also been associated with autoimmunity in humans
(Watanabe and Nakajima, 2012).
Theoretically, therefore, antagonists directed to these immune
inhibitory checkpoints should enable T cells to proliferate and
respond more vigorously and would be beneficial in controlling
virus infections and suppressing tumor growth (Figure 2). Ago-
nists of CTLA-4 or PD-1, on the other hand, may prevent unde-
sirable immune responses as occur in autoimmunity, allergy,
and transplant rejection (Okazaki and Honjo, 2007). In many
cases, cancer cells express the ligand PD-L1 on their surface,
which may restrict tumor-reactive T cell responses by engaging
the inhibitory receptor PD-1. Furthermore, PD-L1 on tumor cells
and the surrounding stromal cells is upregulated by g-interferonCancer Cell 27, April 13, 2015 ª2015 Elsevier Inc. 443
Figure 2. Antibody-Mediated Targeting of Negative Regulators of
T Cell Responses
Anti-CTLA4 monoclonal antibodies can alleviate CTLA4-mediated abrogation
of CD28 signaling in T cells and deplete intra-tumoral regulatory T cells
(Treg cells), which act exogenously to suppress anti-tumor effector T cells.
PD-1/PD-L1 blockade interrupts the PD-L1 tumor adaptive response, which
may be initiated by T-cell-derived g-interferon secretion, inducing PD-L1
expression by the tumor cell, and the induction of PD-1 expression by the
activated T cells.
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Perspectivesecreted by the very activated T cells that have infiltrated the
tumor environment (Iwai et al., 2002). Treg cells, which specif-
ically suppress activated T cells during a normal immune
response to limit collateral damage and autoimmunity, are
recruited to the tumor environment and act as another dampener
that limits the activity of tumor-infiltrating cytotoxic T cells (Cu-
riel, 2007). Treg cells express high levels of immune checkpoint
receptors, including CTLA-4 and PD-1, wherein these inhibitors
of effector T cells paradoxically enhance Treg cell activity. These
receptors may thus serve as targets for antibody-mediated Treg
cell depletion (Simpson et al., 2013) (Figure 2). A deficiency of
CTLA-4 in Treg cells in mice results in the spontaneous develop-
ment of systemic lymphoproliferation, fatal T-cell-mediated
autoimmune disease, and hyperproduction of IgE, and the loss
of CTLA-4 also potentiates tumor immunity (Wing et al., 2008).
Furthermore, the immune-cell-expressed ligand semaphorin-
4a (Sema4a) and the Treg-cell-expressed receptor neuropilin-1
(Nrp1) interact to potentiate Treg cell function and survival.
Nrp1 is required by Treg cells to limit anti-tumor immune re-
sponses, suggesting that the Nrp1-Sema4a pathway may be a
potential target to limit Treg-cell-mediated tumor-induced toler-
ance (Delgoffe et al., 2013).
Inhibitory myeloid cells also accumulate in certain tumor types
and may negatively impact on anti-tumor T cell responses
(reviewed in Ostrand-Rosenberg, 2010).
Monoclonal antibody technology (Ko¨hler and Milstein, 1975)
has enabled a range of immunotherapies targeting cell-surface
molecules. What has recently been achieved with clinical suc-
cess in the case of some tumors, in particular malignant meta-
static melanoma, is the use of blocking monoclonal antibodies
directed against CTLA-4 and PD-1 or PD-L1 (Figure 2). These
allow the specific tumor infiltrating T cells to undergo unre-444 Cancer Cell 27, April 13, 2015 ª2015 Elsevier Inc.stricted proliferation, thereby enhancing their capacity to kill
their tumor targets. The blockade of CTLA-4 using monoclonal
antibodies, as first shown by Allison (Leach et al., 1996), restored
tumor immunity in mice bearing immunogenic tumors. There are
two anti-CTLA-4 antibodies in use againstmetastaticmelanoma:
ipilimumab and tremelimumab. There are eight anti-PD-1/PD-L1
antibodies in clinical trials: nivolumab, pembrolizumab /MK-
3475, pidilizumab, and AMP-224, targeting PD-1; and BMS-
935559, MEDI4736, MPDL3280A, and MSB0010718C, targeting
PD-L1. In addition, inhibitors against other immune checkpoint
regulators expressed on the cell surface, such as TIM3, LAG3,
and VISTA, and agonist antibodies acting on T cell costimulatory
receptors, such as OX40 and CD137, are being developed
for cancer immunotherapy (European Society for Medical
Oncology, 2014). The dual cocktail of ant-CTLA-4 and anti-PD-
1 has been most effective in treating some melanoma patients
(Curran et al., 2010).
Monoclonal antibodies targeting CCR4, a chemokine receptor
that is highly expressed on Treg cells, and PI3 kinase inhibitors
that preferentially block Treg cell activity, may soon complement
the T cell activation checkpoint blockade modulators (e.g., anti-
bodies against CTLA4 or PDL1) in immunotherapy of cancer
(Sugiyama et al., 2013; Abu-Eid et al., 2014).
The Promise of T Cell Engineering
The advent of gene transfer technologies, in particular those
enabling the transduction of human T lymphocytes using gibbon
ape leukemia virus envelope-pseudotyped g-retroviral vectors
(Mavilio et al., 1994; Bunnell et al., 1995; Gallardo et al., 1997),
created new opportunities for immune intervention based on
T cell engineering (Sadelain et al., 2003). Patients’ T cells, easily
accessible in peripheral blood, can be genetically instructed to
target tumors by transduction of receptors for antigen, utilizing
either the physiological TCR (Ho et al., 2003; Stone and Kranz,
2013) or synthetic receptors now known as CARs (Sadelain
et al., 2009). Both approaches have shown clinical successes,
particularly in melanoma (Robbins et al., 2011), targeting NY-
ESO1 (Chen et al., 1997), and in acute lymphoblastic leukemia,
(Brentjens et al., 2013; Grupp et al., 2013; Davila et al., 2014;
Lee et al., 2015; Maude et al., 2014), targeting CD19 (Brentjens
et al., 2003).
CARs are artificial, composite receptors for antigen that
integrate principles of B cell and T cell antigen recognition
(Figure 3A). They are particularly attractive in that they elude hu-
man leucocyte antigen (HLA) restriction and are thus applicable
to all patients irrespective of their HLA haplotypes, unlike TCRs.
CARsmay also overcomeHLA downregulation by tumors, which
deprives T cells of a ligand for their endogenous TCR (Seliger,
2008). The critical function of CARs is, however, not to merely
target the T cells to a tumor antigen, but to enhance T cell func-
tion. Thus, effective CARs further integrate principles of T cell
costimulation (Figures 3B and 3C) and provide a broad spectrum
of functional enhancements acquired by directly soliciting
selected costimulatory pathways (Sadelain et al., 2013; Jensen
and Riddell, 2015).
The CARs that have recently shown impressive clinical out-
comes in patients with B cell malignancies are second-genera-
tion CARs, so named to highlight their fundamental difference
with the CD3z chain fusion receptors that preceded them
Figure 3. Principles of T Cell Engineering
and CAR Design
(A) Integration of B cell and T cell antigen recog-
nition principles in the design of CARs. The heavy
and light chain chains, which are components
of the B cell receptor and Igs, are fused to the
T-cell-activating z chain of the TCR-associated
CD3 complex to generate non-MHC restricted,
activating receptors capable of redirecting T cell
antigen recognition and cytotoxicity.
(B and C) Integration of T cell activation and
costimulation principles in dual signaling CARs
designed to enhance T cell function and persis-
tence in addition to retargeting T cell specificity.
In (B), the physiological abTCR associated with
the CD3 signaling complex is flanked by the CD28
costimulatory receptor. (C) shows a prototypic
second-generation CAR, which comprises three
canonical components: an scFv for antigen
recognition, the cytoplasmic domain of the CD3z
chain for T cell activation, and a costimulatory
domain to enhance T cell function and persistence
(here CD28, as described in Maher et al. [2002],
and currently utilized in ALL patients as reported in
Brentjens et al. [2013] and Davila et al. [2014]).
Unlike the abTCR/CD3 complex, which comprises
g, d, ε, and z signaling chains and is modulated
by a multitude of costimulatory receptors, CARs
possess in a single molecule the ability to trigger
and modulate antigen-specific T cell functions.
Cancer Cell
Perspective(Sadelain et al., 2009). These molecules evolved in three critical
stages.When the z chain of the CD3 complex was independently
cloned by the Weiss, Seed, and Klausner groups, the newly
discovered T-cell-specific chain, which lacks an extracellular
domain (Figure 3B), was fused to CD8, CD4, or CD25 (Irving
and Weiss, 1991; Letourneur and Klausner, 1991; Romeo and
Seed, 1991) to enable antibody-mediated cross-linking of the z
chain fusion receptor. These studies, conducted in leukemic
T cells, revealed the activating function of the z chain. The addi-
tion of an scFv derived from an Ig, first reported by Eshhar and
colleagues (Eshhar et al., 1993; Brocker et al., 1993), diversified
the binding capacity of these fusion receptors and redirected
the specificity of transfected cytotoxic T cell hybridomas (Eshhar
et al., 1996). Having established methods for the transduction of
human peripheral blood T cells (Gallardo et al., 1997), we could
for the first time test the functional features of z-chain-based
CARs in clinically relevant cell types. We found z-chain-basedCancer CellCARs to be unable to command T cell
expansion upon repeated exposure to an-
tigen (Gong et al., 1999), consistent with
the two-signal model of T cell activation
(Lafferty and Cunningham, 1975) and
transgenic mouse studies of first-genera-
tion CARs (Brocker, 2000). These findings
prompted us to combine chimeric costi-
mulatory receptors thatwehadpreviously
studied in human primary T cells (Krause
et al., 1998) with T-cell-activating CARs,
thus creating dual-signaling receptors
(Figure 3C) that we found were able to
instruct human peripheral blood T cells
to expand and retain function upon
repeated exposure to antigen (Maheret al., 2002). These and other contemporary studies (Finney
et al., 1998; Hombach et al., 2001; Imai et al., 2004) paved the
way for engineering persisting functional T cells, which we later
named ‘‘living drugs.’’ Second-generation CARs are a new class
of drugswith exciting potential for cancer immunotherapy (Sade-
lain et al., 2013; Jensen and Riddell, 2015). Recent clinical results
obtainedwithCD19CARsare reviewed inRamoset al. (2014) and
Kochenderfer and Rosenberg (2013). CAR therapy promises to
produce more durable cancer regression in other hematological
malignancies and solid tumors, including those that do not pre-
sent altered self-antigens.
CARs may be combined with costimulatory ligands (Stephan
et al., 2007), chimeric costimulatory receptors (Krause et al.,
1998; Duong et al., 2011; Wilkie et al., 2012; Prosser et al.,
2012; Kloss et al., 2013), or cytokines such as IL-15 (Hoyos
et al., 2010; Markley and Sadelain, 2010) or IL-12 (Chinnasamy
et al., 2012; Chmielewski and Abken, 2012; Pegram et al.,27, April 13, 2015 ª2015 Elsevier Inc. 445
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Unlike CARs, CCRs do not trigger T cell activation, but rather
offset apoptosis and extend T cell persistence in antigen-spe-
cific fashion (Krause et al., 1998). Antigen-specific inhibitory
receptors, such as iCARs modeled on CTLA-4 and PD-1 (Fe-
dorov et al., 2013), further extend this growing panoply of recom-
binant receptors.
In a futuristic embodiment, bringing together thymopoiesis and
cell engineering (Zhao et al., 2007; Themeli et al., 2013), the ability
to recapitulate thymic maturation in vitro and generate T cells
from pluripotent stem cells (Nishimura et al., 2013; Vizcardo
et al., 2013; Themeli et al., 2013) may open a path to design
and manufacture therapeutic T cells with broad histocompatibil-
ity and optimized functional features (Themeli et al., 2015).
Perspective
The spectacular successes that have been achieved in the im-
mune management of various clinical conditions and especially
cancer were borne out of basic research that was creatively
exploited by translational researchers. No one could have pre-
dicted that investigating how or why virus-induced lymphocytic
leukemia needs to develop in the neonatal mouse thymus would
reveal the latter’s immunological function. The extensive world-
wide research that followed was crucial to our understanding
of what cells and molecules regulate T cell activation and how
this may be used to our benefit in the clinic. The advent of
monoclonal antibody and gene transfer technologies later
enabled creative exploitation of fundamental knowledge on
T and B cell antigen recognition, T cell activation, and T cell
costimulation, leading to the invention of checkpoint blockade
and CAR T cell therapy. While some key molecular pathways
and cellular interactions have been decoded, much more is yet
to be discovered. More immunology research is warranted. In
themeantime, immunology has spawned immunotherapy, which
is about to claim a seat in the therapeutic pantheon of oncology,
next to surgery, radiation therapy, and chemotherapy.
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